Silence Therapeutics (SLN) Research & Development (2024 - 2026)

Silence Therapeutics has reported Research & Development for 3 years, with the latest figure at $9.1 million in Q1 2026.

• Quarterly Research & Development fell 56.17% year-over-year to $9.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.8 million (down 66.0% YoY) and the FY2025 annual result came in at $4.8 million, down 92.94% from the prior year.
• Research & Development rose to $9.1 million in Q1 2026 per SLN's latest filing, from $602000.0 in the prior quarter.
• Over five years, Research & Development peaked at $40.2 million in Q4 2024 and troughed at $602000.0 in Q4 2025.
• A 3-year average of $10.5 million and a median of $7.8 million in 2024 frame the typical range for Research & Development.
• The widest YoY moves for Research & Development: up 3224.76% in 2025, down 98.5% in 2025.
• Over 3 years, Research & Development stood at $40.2 million in 2024, then tumbled by 98.5% to $602000.0 in 2025, then surged by 1415.28% to $9.1 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $9.1 million, $602000.0, and $13.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.